# Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

> **NCT01547299** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 52 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Leuprolide
- **DRUG:** Dutasteride

## Key facts

- **NCT ID:** NCT01547299
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-31
- **Primary completion:** 2013-11-30
- **Final completion:** 2013-11-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2018-10-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01547299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01547299, "Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01547299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*